Kenneth H Dinnon

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/6674528/kenneth-h-dinnon-publications-by-year.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37 papers	4,722 citations	22 h-index	42 g-index
42 ext. papers	6,807 ext. citations	19.1 avg, IF	5.46 L-index

#	Paper	IF	Citations
37	Stabilized coronavirus spike stem elicits a broadly protective antibody. *Cell Reports*, **2021**, 37, 109929	10.6	18
36	Critical ACE2 Determinants of SARS-CoV-2 and Group 2B Coronavirus Infection and Replication. *MBio*, **2021**, 12,	7.8	3
35	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung. *Nature Communications*, **2021**, 12, 3587	17.4	17
34	SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. *Nature*, **2021**, 591, 451-457	50.4	131
33	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. *Immunity*, **2021**, 54, 1869-1882.e6	32.3	16
32	Protective Efficacy of Rhesus Adenovirus COVID-19 Vaccines against Mouse-Adapted SARS-CoV-2. *Journal of Virology*, **2021**, 95, e0097421	6.6	3
31	Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection. *PLoS Pathogens*, **2021**, 17, e1009897	7.6	11
30	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. *Vaccines*, **2020**, 8,	5.3	38
29	SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. *Cell*, **2020**, 182, 429-446.e14	56.2	710
28	Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. *Cell Reports*, **2020**, 32, 107940	10.6	260
27	An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. *Science Translational Medicine*, **2020**, 12,	17.5	534
26	Acute SARS-CoV-2 Infection is Highly Cytopathic, Elicits a Robust Innate Immune Response and is Efficiently Prevented by EIDD-2801 **2020**,		5
25	Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice **2020**,		15
24	A mouse-adapted SARS-CoV-2 model for the evaluation of COVID-19 medical countermeasures **2020**,		58
23	SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness **2020**,		62
22	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate **2020**,		8
21	A Newcastle disease virus (NDV) expressing membrane-anchored spike as a cost-effective inactivated SARS-CoV-2 vaccine **2020**,		13

20	Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 **2020**,		10
19	SARS-CoV-2 D614G Variant Exhibits Enhanced Replication and Earlier Transmission **2020**,		41
18	Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *Journal of Virology*, **2020**, 94,	6.6	116
17	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. *Nature*, **2020**, 586, 560-566	50.4	299
16	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. *Cell*, **2020**, 183, 1070-1085.e12	56.2	224
15	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. *Nature*, **2020**, 586, 567-571	50.4	594
14	Swine acute diarrhea syndrome coronavirus replication in primary human cells reveals potential susceptibility to infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 26915-26925	11.5	49
13	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. *EBioMedicine*, **2020**, 62, 103132	8.8	39
12	A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 32657-32666	11.5	37
11	SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. *Science*, **2020**, 370, 1464-1468	33.3	517
10	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. *Cell*, **2020**, 183, 1367-1382.e17	56.2	217
9	Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. *Antiviral Research*, **2019**, 169, 104541	10.8	288
8	Shortening of Zika virus CD-loop reduces neurovirulence while preserving antigenicity. *PLoS Neglected Tropical Diseases*, **2019**, 13, e0007212	4.8	4
7	Dual regulation of decorin by androgen and Hedgehog signaling during prostate morphogenesis. *Developmental Dynamics*, **2018**, 247, 679-685	2.9	1
6	Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines. *Journal of Virology*, **2018**, 92,	6.6	48
5	An Immunocompetent Mouse Model of Zika Virus Infection. *Cell Host and Microbe*, **2018**, 23, 672-685.e6	23.4	129
4	CD-loop Extension in Zika Virus Envelope Protein Key for Stability and Pathogenesis. *Journal of Infectious Diseases*, **2017**, 216, 1196-1204	7	12
3	MERS-CoV Accessory ORFs Play Key Role for Infection and Pathogenesis. *MBio*, **2017**, 8,	7.8	99

2	Middle East Respiratory Syndrome Coronavirus Nonstructural Protein 16 Is Necessary for Interferon Resistance and Viral Pathogenesis. *MSphere*, **2017**, 2,	5	71
1	Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. *SSRN Electronic Journal*,	1	11